June 12, 2020 / 11:13 AM / a month ago

BRIEF-Imara Presents Positive Interim Results From Phase 2A Study Of IMR-687 In Sickle Cell Disease

June 12 (Reuters) - Imara Inc:

* IMARA PRESENTS POSITIVE INTERIM RESULTS FROM PHASE 2A STUDY OF IMR-687 IN SICKLE CELL DISEASE AT THE VIRTUAL EUROPEAN HEMATOLOGY ASSOCIATION ANNUAL CONGRESS

* IMARA - IMR-687 WAS WELL TOLERATED AS A MONOTHERAPY AND IN COMBINATION WITH HYDROXYUREA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below